FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application by Prasco Laboratories to market a Calcipotriene and Betamethrone Dipropionate product for treating plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Calcipotriene and Betamethasone Dipropionate (Calcipotriene and Betamethasone Dipropionate)

Snippet

SUPPL AP for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)